Recurrent anaphylaxis to a gelatin-based colloid plasma substitute and to cetuximab following sensitisation to galactose-alpha-1,3-galactose

Br J Anaesth. 2021 Jun;126(6):e200-e202. doi: 10.1016/j.bja.2021.02.013. Epub 2021 Mar 31.
No abstract available

Keywords: anaphylaxis; cetuximab; colloid; epitope; galactose-alpha-1,3-galactose; gelatin; glycosylated.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Anaphylaxis / blood
  • Anaphylaxis / chemically induced*
  • Anaphylaxis / diagnosis
  • Anaphylaxis / immunology
  • Antineoplastic Agents, Immunological / adverse effects*
  • Biomarkers / blood
  • Cetuximab / adverse effects*
  • Disaccharides / immunology*
  • Drug Hypersensitivity / blood
  • Drug Hypersensitivity / diagnosis
  • Drug Hypersensitivity / etiology*
  • Drug Hypersensitivity / immunology
  • Epitopes
  • Humans
  • Immunoglobulin E / blood*
  • Male
  • Plasma Substitutes / adverse effects*
  • Polygeline / adverse effects*
  • Risk Factors

Substances

  • Antineoplastic Agents, Immunological
  • Biomarkers
  • Disaccharides
  • Epitopes
  • Plasma Substitutes
  • galactosyl-(1-3)galactose
  • Immunoglobulin E
  • Polygeline
  • Cetuximab